Although BACE-1 inhibitors prevent β-amyloid aggregation in AD patients, some of these drugs which are currently being developed have been dropped due to their toxic nature, and it is rather too early to discover whether any of these agents could be effective in the management of AD [7]. Here, BACE1 is linked to Alzheimer disease.